US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Allergy · Allergic rhinoconjunctivitis
A. MENARINI MANUFACTURING
A. Menarini Industrie Farmaceutiche Riunite s.r.l.
A. MENARINI MANUFACTURING drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Florence, IT HQ
122 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Florence, IT
- Employees
- 122
- Programs
- 2
- Drugs
- 6
- Patents
- 5
A. MENARINI MANUFACTURING pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
A. MENARINI MANUFACTURING drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
desloratadine
Respiratory system (R01)US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to A. MENARINI MANUFACTURING in public FDA and regional records.
-
Development asset linked to A. MENARINI MANUFACTURING in public FDA and regional records.
-
Development asset linked to A. MENARINI MANUFACTURING in public FDA and regional records.